Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Teresa Sirois

Nurse Practitioner, Family Topsham, ME Nurse Practitioner

NPI 1396779757 CMS profile 773112

105 Topsham Fair Mall Rd Unit 1, Topsham, ME 04086

Open in the dashboard

General payments

$1,861

64 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Teresa Sirois of Topsham, ME is reported in the CMS Open Payments database as having received $1,861 across 64 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $722 26
2024 General $214 10
2023 General $359 8
2022 General $407 12
2021 General $159 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Teresa Sirois
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Teresa Sirois were reported at $722. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Teresa Sirois Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $159 $124 $35–$379 $132
2022 $407 $141 $44–$430 $149
2023 $359 $154 $49–$476 $160
2024 $214 $165 $51–$504 $164
2025 $722 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $242 7 payments
  2. Janssen Biotech, Inc. $214 5 payments
  3. Incyte Corporation $212 7 payments
  4. AbbVie, Inc. $207 8 payments
  5. Pharmacyclics LLC, An AbbVie Company $179 7 payments
  6. Mirati Therapeutics, Inc. $114 1 payment
  7. Rigel Pharmaceuticals, Inc. $84 1 payment
  8. Takeda Pharmaceuticals U.S.A., Inc. $71 4 payments
  9. E.R. Squibb & Sons, L.L.C. $69 2 payments
  10. Daiichi Sankyo Inc. $62 3 payments
  11. Other $406 19 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,662 62 payments
  2. Education $199 2 payments
Products named General payments · program years 2021–2025
  1. IMBRUVICA $238 9 payments
  2. DARZALEX $127 2 payments
  3. EPKINLY $124 4 payments
  4. KRAZATI $114 1 payment
  5. AIRSUPRA $94 1 payment
  6. Tavalisse $84 1 payment
  7. JAKAFI $70 3 payments
  8. OPDIVO $69 2 payments
  9. MONJUVI $61 4 payments
  10. NINLARO $54 3 payments
  11. Other $795 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

590

Median for Nurse Practitioner: 389

Drug cost

$33,145

Median for Nurse Practitioner: $21,885

Branded share of claims

23.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 20 $20,854
Fentanyl Generic 35 $4,702
Ondansetron Odt Ondansetron Brand 68 $1,250
Morphine Sulfate Generic 22 $1,053
Oxycodone Hcl Generic 58 $689
Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine Brand 16 $659
Prochlorperazine Maleate Generic 45 $461
Acyclovir Generic 21 $439
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $397
Potassium Chloride Generic 39 $372

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$68,533

Of which drugs: $49,689

Medicare patients

115

Average age 75

Services billed

4,161

60 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 55%
Arthritis 43%
Chronic kidney disease 31%
Depression 27%
Ischemic heart disease 26%
Diabetes 22%
Heart failure 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Infusion, normal saline solution , 1000 cc J7030 Office 17 21 $41

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
IMBRUVICA
  • AbbVie, Inc. $59
$59 — —
ENHERTU
  • AstraZeneca Pharmaceuticals LP $25
$25 — —
IMFINZI
  • AstraZeneca Pharmaceuticals LP $24
$24 — —
NINLARO
  • Takeda Pharmaceuticals U.S.A., Inc. $21
$21 — —
Udenyca
  • Coherus Biosciences Inc. $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

64 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Maine

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record